Legal
Ingenza is pleased to announce that Syngenta is exercising its commercial licensing option for a technology that enables the development of innovative crop protection products.
Noted biotech investor G. Steven Burrill will only spend 30 months in jail for his involvement in wire fraud and tax evasion. Burrill pleaded guilty to the charges last year and, at the time, faced up to 30 years in prison. Now, he will serve less than one-tenth of that amount.
Prior to being acquired by Medtronic, the two companies were involved in what the DOJ called kickback schemes to encourage unauthorized use of a medical device.
The year 2018 saw a number of significant triumphs in the biopharma industry – increased numbers of drug approvals and near record-shattering IPOs, but the industry also saw its share of blemishes and black eyes from various corners of the globe.
Shareholders raise concern over the fairness of the reverse merger and question potential conflicts of interest of OvaScience’s co-founder.
Many of these directors do not publicly disclose their affiliation with the pharma companies in their nonprofit biographies, report shows.
The U.S. Food and Drug Administration (FDA) issued a warning letter to Faro Owiesy, a researcher and physician at the California-based Corona Doctors Medical Clinics, for violating a clinical hold. In addition, the agency warned Owiesy for giving an investigational drug to patients before an investigational new drug (IND) application was approved.
David Johnston, the former chief financial officer of AVEO Oncology, was found guilty of misleading investors about the company’s kidney cancer drug, Tivozanib. Under new leadership, AVEO aims to seek U.S. approval for its kidney cancer drug early next year.
Seven African American seek unspecified damages over allegations of discrimination at Charleston, S.C. facility.
First-in-class enterprise workflow platform for streamlining cell line development operations
PRESS RELEASES